Fig. 4: SLC25A10 inhibits ferroptosis in cervical cancer cells.
From: SLC25A10 promotes cisplatin resistance by inhibiting ferroptosis in cervical cancer
GO analysis revealed that SLC25A10 is involved in various types of cellular metabolism, including lipid metabolism, oxidation‒reduction, carboxylic acid metabolism, and programmed cell death (A). KEGG analysis suggested that SLC25A10 is associated with iron ion transmembrane transporter activity and iron ion transport (B). The death of CaSki and HeLa cells with SLC25A10 overexpression or knockdown was detected after 24 h of treatment with different concentrations of RSL3 or erastin (C–J). The morphological changes in the cells were observed by microscopy (C, D, G, H). The viability of cells with either high or low SLC25A10 expression was evaluated by CCK-8 assay (E, F, I, J). Compared with the control group, *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. Scale =10 µm. The data represent the means ± SDs.
